Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 9/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.45 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1381190 | 0.87 | HTR3A (0.51) | CYP1A2CYP3A4CYP2D6HTR6HTR1A | |
| SCHEMBL3615298 | 0.86 | MEN1 (0.52) | KEAP1NFE2L2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1378323 | 0.85 | ALDH1A1 (0.49) | USP2CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL1380811 | 0.84 | SCN9A (0.49) | GBA1HTR6HTR1AHTR2AHTR2C | |
| SCHEMBL1380690 | 0.82 | GBA1 (0.51) | KEAP1NFE2L2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1379933 | 0.82 | SCN9A (0.47) | MAPK1GBA1HTR6HTR1AHTR2A | |
| SCHEMBL1379060 | 0.81 | HTR6 (0.47) | USP2CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL4769222 | 0.79 | MAPT (0.47) | KEAP1NFE2L2GBA1HTR6HTR1A | |
| SCHEMBL3623707 | 0.78 | HTR6 (0.46) | CYP1A2CYP3A4CYP2D6HTR6HTR7 | |
| SCHEMBL1378203 | 0.78 | KDM4E (0.52) | CYP1A2CYP3A4CYP2D6ALPLHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4731114-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | claimed |
| US-20070066599-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | claimed |
| EP-1412325-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2004-04-28 | — | — | EP | claimed |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-21 | — | — | US | claimed |
| WO-2002100822-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2002-12-19 | — | — | WO | claimed |
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | disclosed |
| US-7572787-B2 | Substituted naphthalene sulfonamides | BIOVITRUM AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066599-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | disclosed |
| US-7144883-B2 | Bicyclic sulfonamide compounds | BIOVITRUM AB (SE) | 2006-12-05 | — | — | US | disclosed |
| EP-1412325-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-21 | — | — | US | disclosed |
| WO-2002100822-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066599-A1 | New compounds | SULT2A1, GPR119, STS | KEAP1 1645/4885NFE2L2 597/4885USP2 2018/4885 |
| US-20070066598-A1 | Compounds | SULT2A1, STS, SLC5A2 | KEAP1 1144/4885NFE2L2 406/4885USP2 2276/4885 |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | SULT2A1, SULT1A1, SULT1E1 | KEAP1 309/4885NFE2L2 24/4885USP2 1848/4885 |
| US-20070066600-A1 | Compounds | SULT2A1, STS, SLC5A2 | KEAP1 1144/4885NFE2L2 406/4885USP2 2276/4885 |
| US-20100222330-A1 | New Compounds | SULT2A1, GPR119, STS | KEAP1 1645/4885NFE2L2 597/4885USP2 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.